Here are three things to know.
1. International Orthopaedics’ portfolio of orthopedic implants will be supplemented with C-ment, a line of PMMA bone cements with and without gentamycin, the ACL reconstruction solution X-Grip system, eTiss allografts processed with Leader Biomedical’s proprietary eCOO Technology using supercritical carbon dioxide, and the Ossfinity and OssGro line of synthetic grafts produced with proprietary MBCP Technology.
2. Leader Biomedical discontinued their partnership with aap Joints in 2017 and an increased investment into BioTiss early in 2018.
3. Leader Biomedical’s acquisition of International Orthopaedics is the company’s latest investment, following its expansions into India, Brazil, Russia and Malaysia in 2016 and the U.S. in 2017.
More articles on devices and implants:
Dr. Kornelis Poelstra completes 300th spine procedure with Mazor X — 5 highlights
Global thoracolumbar spine devices to grow at 4% CAGR through 2022: 4 observations
Curbing opioid use for vertebral compression fractures with balloon kyphoplasty
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
